


IMAGE OF THE MONTH

Choroid Metastasis From Human Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer



Tomonobu Koizumi,¹ Noriko Yoshida,² and Kai Mizuhata³

¹Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan; ²Department of Ophthalmology, Shinshu University School of Medicine, Matsumoto, Japan; and ³Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan



A 39-year-old man with human epidermal growth factor receptor type 2-positive gastric cancer with hepatic metastasis had been treated with first-line chemotherapy consisting of trastuzumab + S-1 + oxaliplatin followed by trastuzumab deruxtecan for 18 months. Endoscopic examination showed a mass in the esophagogastric junction (Figure A), but disease remained stable during chemotherapy. He was referred to the ophthalmology department of our hospital due to visual impairment in the right eye. The right eye showed a mass on the superior subretinal space at 1- to 3-o'clock position with secondary serous retinal detachment in the inferior eye

(Figure B) suggesting a metastatic tumor. Coronal magnetic resonance imaging showed a smooth and sharply margined tumor in the right eye with low-intensity signals on Dixon T2-weighted imaging (Figure C). Based on the clinical course, a diagnosis of choroid metastasis of gastric cancer was made.

Most current article

Copyright © 2022 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

2772-5723

<https://doi.org/10.1016/j.gastha.2022.09.002>

The tumor size in the right eye was reduced after radiotherapy (3 Gy \times 10 fractions), but this failed to improve the visual impairment. Choroid metastasis in patients with gastric cancer is extremely rare. In addition, there have been no previous case reports regarding the development of choroid and/or eye metastasis in cases of human epidermal growth factor receptor type 2-positive gastric cancer.

Received August 29, 2022. Accepted September 6, 2022.

Correspondence:

Address correspondence to: Tomonobu Koizumi, MD, Department of

Hematology and Medical Oncology, Shinshu University of School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano Prefecture 390-8621, Japan.. e-mail: tomonobu@shinshu-u.ac.jp.

Conflict of Interest:

The authors disclose no conflicts.

Funding:

The authors report no funding.

Ethical Statement:

The corresponding author, on behalf of all authors, jointly and severally, certifies that their institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.